{"filing":{"accession_number":"0001140361-26-025667","cik":"0001444192","ticker":"GRCE","company_name":"Grace Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"ef20076145_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_8k.htm"},"events":[{"id":11708,"run_id":10291,"accession_number":"0001140361-26-025667","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Grace Therapeutics issued a press release on June 18, 2026 announcing financial results for the fiscal year ended March 31, 2026, including net loss of $7.8 million, R\u0026D expenses of $2.4 million, and cash position of $17.0 million. The filing is made pursuant to Item 2.02 \"Results of Operations and Financial Condition\" with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. While the release also discusses regulatory developments (FDA Complete Response Letter and Type A meeting), the core disclosure is the fiscal year-end financial results.","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8363,"accession_number":"0001140361-26-025667","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics issued a press release on June 18, 2026 announcing financial results for the fiscal year ended March 31, 2026, including net loss of $7.8 million, R\u0026D expenses of $2.4 million, and cash position of $17.0 million. The filing is made pursuant to Item 2.02 \"Results of Operations and Financial Condition\" with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. While the release also discusses regulatory developments (FDA Complete Response Letter and Type A meeting), the core disclosure is the fiscal year-end financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:02:23.271268+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8363,"accession_number":"0001140361-26-025667","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Grace Therapeutics issued a press release on June 18, 2026 announcing financial results for the fiscal year ended March 31, 2026, including net loss of $7.8 million, R\u0026D expenses of $2.4 million, and cash position of $17.0 million. The filing is made pursuant to Item 2.02 \"Results of Operations and Financial Condition\" with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. While the release also discusses regulatory developments (FDA Complete Response Letter and Type A meeting), the core disclosure is the fiscal year-end financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:02:23.271268+00:00","company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","filing_date":"2026-06-18"}]}